Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Treosulfane · 1 trial · 1 indication
To investigate the effect of a treatment with Imatinib mesylate, Pioglitazone , Etoricoxib, and Dexamethasone in combination with metronomic chemotherapy (Treosulfane) on the PSA response rate in patients with hormone refractory prostate cancer. A patient will be defined as a responder if a PSA decline of at least 50%, which must be confirmed by a second PSA value 4 weeks later, is observed. A patient will be defined as a non-responder if PSA has not decreased during treatment. Non-response is defined as a 25% increase over the baseline on-study which is confirmed (equal or more) by a second value 4 weeks apart. The absolute increase must account for \> 5 ng/ml.
| Arm | Type | Description |
|---|---|---|
| STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane | EXPERIMENTAL | STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks |
| Name | Type | Description |
|---|---|---|
| imatinib mesylate | DRUG | - |
| Treosulfane | DRUG | - |
| etoricoxib | DRUG | - |
| pioglitazone | DRUG | - |
| dexamethasone | DRUG | - |
Inclusion criteria: * Histologically confirmed prostate carcinoma, which has proven progression after primary hormone therapy (surgical or medicinal castration). * Patients must have increasing PSA levels (within 3 months prior to enrollment) with at least two consecutively increasing PSA levels. *...
Top 20 of 53 competitors
Treosulfane is an investigational small molecule being studied for the treatment of prostate cancer, specifically in patients with hormone-refractory prostate cancer. It is being evaluated as part of a combined anti-inflammatory and angiostatic therapy approach. The drug is currently in Phase 2 clinical development and is not yet approved.
Treosulfane is a small molecule with anti-inflammatory and angiostatic properties. It is being studied for its potential to inhibit angiogenesis and reduce inflammation in the context of hormone-refractory prostate cancer. However, its specific molecular target has not been disclosed in the available information.
Treosulfane is being developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with prostate cancer.
Treosulfane is in Phase 2 clinical development. It has completed one Phase 2 trial in patients with hormone-refractory prostate cancer. The drug is still investigational and has not received regulatory approval for any indication.
Treosulfane has been studied in one clinical trial with the identifier NCT00427999. This Phase 2 trial, titled 'Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer,' was completed in Germany and enrolled 67 male patients aged 18 years and older.
Treosulfane is also known as Treosulfan. Both names refer to the same drug substance. In clinical literature and trial registries, the drug may be listed under either name, but they are interchangeable.